Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1925 1
1927 2
1966 2
1968 1
1970 1
1980 1
1981 2
1982 3
1983 2
1984 2
1986 3
1988 1
1989 2
1990 2
1991 4
1993 2
1994 1
1995 3
1996 2
1997 8
1998 3
1999 2
2000 7
2001 6
2002 8
2003 8
2004 3
2005 6
2006 4
2007 9
2008 11
2009 8
2010 14
2011 18
2012 16
2013 14
2014 16
2015 21
2016 23
2017 19
2018 17
2019 19
2020 12
2021 26
2022 24
2023 2
Text availability
Article attribute
Article type
Publication date

Search Results

330 results
Results by year
Filters applied: . Clear all
Page 1
Mitophagy in tumorigenesis and metastasis.
Poole LP, Macleod KF. Poole LP, et al. Cell Mol Life Sci. 2021 Apr;78(8):3817-3851. doi: 10.1007/s00018-021-03774-1. Epub 2021 Feb 13. Cell Mol Life Sci. 2021. PMID: 33580835 Free PMC article. Review.
Cysteine oxidation of copper transporter CTR1 drives VEGFR2 signalling and angiogenesis.
Das A, Ash D, Fouda AY, Sudhahar V, Kim YM, Hou Y, Hudson FZ, Stansfield BK, Caldwell RB, McMenamin M, Littlejohn R, Su H, Regan MR, Merrill BJ, Poole LB, Kaplan JH, Fukai T, Ushio-Fukai M. Das A, et al. Among authors: poole lb. Nat Cell Biol. 2022 Jan;24(1):35-50. doi: 10.1038/s41556-021-00822-7. Epub 2022 Jan 13. Nat Cell Biol. 2022. PMID: 35027734 Free PMC article.
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.
Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Laktionov K, Kim SW, Ursol G, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Shi X, Poole L, Peters S, Garon EB, Mok T; POSEIDON investigators. Johnson ML, et al. Among authors: poole l. J Clin Oncol. 2022 Nov 3:JCO2200975. doi: 10.1200/JCO.22.00975. Online ahead of print. J Clin Oncol. 2022. PMID: 36327426
Redox proteins.
Poole LB, Thorpe C. Poole LB, et al. Protein Sci. 2019 Jan;28(1):5-7. doi: 10.1002/pro.3555. Protein Sci. 2019. PMID: 30461094 Free PMC article. No abstract available.
Roxadustat for anemia in patients with end-stage renal disease incident to dialysis.
Provenzano R, Shutov E, Eremeeva L, Korneyeva S, Poole L, Saha G, Bradley C, Eyassu M, Besarab A, Leong R, Liu CS, Neff TB, Szczech L, Yu KP. Provenzano R, et al. Among authors: poole l. Nephrol Dial Transplant. 2021 Aug 27;36(9):1717-1730. doi: 10.1093/ndt/gfab051. Nephrol Dial Transplant. 2021. PMID: 33629100 Clinical Trial.
Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
Provenzano R, Besarab A, Wright S, Dua S, Zeig S, Nguyen P, Poole L, Saikali KG, Saha G, Hemmerich S, Szczech L, Yu KH, Neff TB. Provenzano R, et al. Among authors: poole l. Am J Kidney Dis. 2016 Jun;67(6):912-24. doi: 10.1053/j.ajkd.2015.12.020. Epub 2016 Feb 2. Am J Kidney Dis. 2016. PMID: 26846333 Free article. Clinical Trial.
Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients.
Besarab A, Chernyavskaya E, Motylev I, Shutov E, Kumbar LM, Gurevich K, Chan DT, Leong R, Poole L, Zhong M, Saikali KG, Franco M, Hemmerich S, Yu KH, Neff TB. Besarab A, et al. Among authors: poole l. J Am Soc Nephrol. 2016 Apr;27(4):1225-33. doi: 10.1681/ASN.2015030241. Epub 2015 Oct 22. J Am Soc Nephrol. 2016. PMID: 26494833 Free PMC article. Clinical Trial.
330 results